PT  - JOURNAL ARTICLE
AU  - Ceballos, Francisco C.
AU  - Ryan, Pablo
AU  - Gómez-Casero, Rafael Blancas
AU  - Martin-Vicente, María
AU  - Vidal-Alcántara, Erick Joan
AU  - Peréz-García, Felipe
AU  - Bartolome, Sofía
AU  - Churruca-Sarasqueta, Juan
AU  - Virseda-Berdices, Ana
AU  - Martínez-González, Oscar
AU  - Brochado-Kith, Oscar
AU  - Rava, Marta
AU  - Vilches-Medkouri, Carolina
AU  - Blanca-López, Natalia
AU  - Martinez-Acitores, Ignacio Ramirez
AU  - Moreira-Escriche, Patricia
AU  - De Juan, Carmen
AU  - Resino, Salvador
AU  - Fernández-Rodríguez, Amanda
AU  - Jiménez-Sousa, María Ángeles
TI  - Is coagulation-protein consumption upon admission linked to COVID-19 severity and mortality?
AID  - 10.1101/2021.04.19.21255747
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.19.21255747
4099  - http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255747.short
4100  - http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255747.full
AB  - The link between coagulation system disorders and COVID-19 has not yet been fully elucidated. With the aim of evaluating the association of several coagulation proteins with COVID-19 severity and mortality, we performed a cross-sectional study in 134 patients classified according to the highest disease severity reached during the disease. We found higher levels of antithrombin, prothrombin, factor XI, factor XII and factor XIII in asymptomatic/mild and moderate COVID-19 patients than healthy individuals. Interestingly, decreased levels of antithrombin, factor XI, XII and XIII were observed in those patients who eventually developed severe illness. Additionally, survival models showed us that patients with lower levels of these coagulation proteins had an increased risk of death. In conclusion, COVID-19 provokes early increments of some specific coagulation proteins in most patients. However, lower levels of these proteins at diagnosis might “paradoxically” imply a higher risk of progression to severe disease and COVID-19-related mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant number COV20/1144 [MPY224/20] to AFR/MAJS). AFR, MAJS and MR are Miguel Servet researchers supported and funded by ISCIII (grant numbers: CP14CIII/00010 to AFR, CP17CIII/00007 to MAJS and CP19CIII/00002 to MR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethics Committee of the Institute of Health Carlos III (PI 33_2020-v3) and the Ethics Committee of each hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability on request.